Zomedica Statistics
Total Valuation
Zomedica has a market cap or net worth of $142.09 million. The enterprise value is $61.63 million.
| Market Cap | 142.09M |
| Enterprise Value | 61.63M |
Important Dates
The next estimated earnings date is Thursday, August 8, 2024, after market close.
| Earnings Date | Aug 8, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Zomedica has 979.95 million shares outstanding.
| Shares Outstanding | 979.95M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.47 |
| Forward PS | 5.43 |
| PB Ratio | 0.61 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.37 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 11.50, with a Debt / Equity ratio of 0.01.
| Current Ratio | 11.50 |
| Quick Ratio | 10.66 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -304.32 |
Financial Efficiency
Return on equity (ROE) is -14.80% and return on invested capital (ROIC) is -19.67%.
| Return on Equity (ROE) | -14.80% |
| Return on Assets (ROA) | -14.00% |
| Return on Capital (ROIC) | -19.67% |
| Revenue Per Employee | $180,319 |
| Profits Per Employee | -$255,319 |
| Employee Count | 144 |
| Asset Turnover | 0.10 |
| Inventory Turnover | 2.14 |
Taxes
| Income Tax | -1.70M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -29.27% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -29.27% |
| 50-Day Moving Average | 0.15 |
| 200-Day Moving Average | 0.16 |
| Relative Strength Index (RSI) | 44.79 |
| Average Volume (20 Days) | 3,821,328 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Zomedica had revenue of $25.97 million and -$36.77 million in losses. Loss per share was -$0.04.
| Revenue | 25.97M |
| Gross Profit | 17.60M |
| Operating Income | -46.11M |
| Pretax Income | -38.47M |
| Net Income | -36.77M |
| EBITDA | -37.34M |
| EBIT | -38.34M |
| Loss Per Share | -$0.04 |
Balance Sheet
The company has $82.96 million in cash and $2.50 million in debt, giving a net cash position of $80.46 million or $0.08 per share.
| Cash & Cash Equivalents | 82.96M |
| Total Debt | 2.50M |
| Net Cash | 80.46M |
| Net Cash Per Share | $0.08 |
| Equity (Book Value) | 231.90M |
| Book Value Per Share | 0.24 |
| Working Capital | 84.06M |
Cash Flow
In the last 12 months, operating cash flow was -$19.31 million and capital expenditures -$12.70 million, giving a free cash flow of -$32.01 million.
| Operating Cash Flow | -19.31M |
| Capital Expenditures | -12.70M |
| Free Cash Flow | -32.01M |
| FCF Per Share | -$0.03 |
Margins
Gross margin is 67.78%, with operating and profit margins of -177.59% and -141.59%.
| Gross Margin | 67.78% |
| Operating Margin | -177.59% |
| Pretax Margin | -148.16% |
| Profit Margin | -141.59% |
| EBITDA Margin | -143.82% |
| EBIT Margin | -147.67% |
| FCF Margin | -123.28% |
Dividends & Yields
Zomedica does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -25.87% |
| FCF Yield | -22.53% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Zomedica has an Altman Z-Score of 6.19 and a Piotroski F-Score of 2.
| Altman Z-Score | 6.19 |
| Piotroski F-Score | 2 |